IP Library › Granted Patent US 12,168,039
Granted Patent B2
US 12,168,039 · App. 18/447,049 · Granted Dec 17, 2024

Anti-inflammatory peptides and composition comprising the same

Inventors: Sang Jae Kim (Seoul, KR); Kyung Hee Kim (Seoul, KR); Kyu-Yong Lee (Seoul, KR); Seong-Ho Koh (Seoul, KR); Hyun-Hee Park (Seoul, KR); Sung Jin Huh (Seoul, KR); Woo Jin Lee (Seoul, KR); Bum Joon Kim (Daejeon, KR)
Assignee: GemVax & KAEL CO., LTD.
A61K38/45A23L33/18A61K8/64A61Q19/00C07K7/08C07K14/4703C12N9/0069C12N9/0083C12Y113/11C12Y114/99001C12Y207/07049A23V2002/00A61K38/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,039
App. No.
18/447,049
Granted
Dec 17, 2024
Kind
B2
Abstract

The present invention relates to a method of treating autoimmune disease comprising administering to a subject in need thereof a composition comprising an isolated peptide of SEQ ID NO: 1.

Claims (8)

1. A method for treating autoimmune disease comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1, wherein the autoimmune disease is thyroiditis, lupus, Goodpasture's syndrome, allograft rejection, graft versus host disease, or diabetes.

2. The method of claim 1 , wherein the composition is administered orally, rectally, transdermally, intravenously, intramuscularly, intraperitoneally, in the bone marrow, epidurally, or subcutaneously.

3. The method of claim 1 , wherein the composition comprises the isolated peptide at a concentration of 0.1 μg/mg to 1 mg/mg.

4. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.1 μg/kg to 1.0 g/kg body weight of the subject.

5. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 1 μg/kg to 10 mg/kg body weight of the subject.

6. The method according to claim 1 , wherein the peptide is administered 1 to 3 times a day.

7. The method of claim 1 , wherein the peptide is administered at a daily dose of 0.1 μg/kg to 1.0 g/kg body weight of the subject.

8. The method of claim 1 , wherein the peptide is administered 1 to 3 times daily.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 068509/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2024
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 067478/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2024
From: KIM, KYUNG HEE; LEE, KYU-YONG; KOH, SEONG-HO; PARK, HYUN-HEE; HUH, SUNG JIN; LEE, WOO JIN; KIM, BUM JOON
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 067478/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2024
From: GEMVAX & KAEL CO., LTD.
To: KIM, SANG JAE; GEMVAX & KAEL CO., LTD.
Reel/Frame 067478/0113 →
Priority Claims (6)
KR 10-2012-0050529 · May 11, 2012 · national
KR 10-2012-0050533 · May 11, 2012 · national
KR 10-2012-0071989 · Jul 2, 2012 · national
KR 10-2012-0104144 · Sep 12, 2012 · national
KR 10-2012-0104207 · Sep 19, 2012 · national
WO PCT/EP2013/055329 · Mar 15, 2013 · international
Continuity (6)
Division 17835278 · Jun 8, 2022
Division 17080653 · Oct 26, 2020
Division 16025352 · Jul 2, 2018
Division 15343502 · Nov 4, 2016
Division 14400291
Related Publication 20240000902A1 · Jan 4, 2024